Editas Medicine completes follow-on

On March 16, gene editing company Editas Medicine Inc. (NASDAQ:EDIT) raised $90 million through the sale of 4 million shares at $22.50 in a follow-on underwritten by Morgan Stanley, JPMorgan, Cowen a...